{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:28:14Z","timestamp":1761017294816,"version":"3.44.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.taap.2020.114976","type":"journal-article","created":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T12:08:08Z","timestamp":1585138088000},"page":"114976","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Towards a comprehensive safety understanding of granulocyte-colony stimulating factor biosimilars in treating chemotherapy associated febrile neutropenia: Trends from decades of data"],"prefix":"10.1016","volume":"395","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3308-1655","authenticated-orcid":false,"given":"Shruti","family":"Rastogi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6745-8230","authenticated-orcid":false,"given":"Shatrunajay","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arvind Kumar","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Sarwat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranay","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tridiv","family":"Katiyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivekanandan","family":"Kalaiselvan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gyanendra Nath","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2020.114976_bb0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.taap.2020.114976_bb0010","first-page":"1","article-title":"Real-world safety experience of tevagrastim\/ratiograstim\/biograstim and tbo-filgrastim, short-acting recombinant human granulocyte colony-stimulating factors","author":"Abboud","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.taap.2020.114976_bb0015","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/clpt.2010.111","article-title":"Pharmacovigilance data mining with methods based on false discovery rates: a comparative simulation study","volume":"88","author":"Ahmed","year":"2010","journal-title":"Clin. Pharmacol. Therap."},{"key":"10.1016\/j.taap.2020.114976_bb0020","first-page":"478","article-title":"Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4-year, single institute experience with different conditioning regimens","volume":"13","author":"Bassi","year":"2015","journal-title":"Blood Transfus."},{"key":"10.1016\/j.taap.2020.114976_bb0025","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00002018-200730070-00011","article-title":"Bayesian confidence propagation neural network","volume":"30","author":"Bate","year":"2007","journal-title":"Drug Saf."},{"key":"10.1016\/j.taap.2020.114976_bb0030","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMct1210890","article-title":"Colony-stimulating factors for febrile neutropenia during cancer therapy","volume":"368","author":"Bennett","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.taap.2020.114976_bb0035","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.bbmt.2017.07.023","article-title":"Results of a prospective randomized, open-label, noninferiority study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in combination with Plerixafor for autologous stem cell mobilization in patients with multiple myeloma and non-Hodgkin lymphoma","volume":"23","author":"Bhamidipati","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.taap.2020.114976_bb0040","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/annonc\/mdv281","article-title":"Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy","volume":"26","author":"Blackwell","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.taap.2020.114976_bb0045","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/trf.12770","article-title":"Biosimilar granulocyte\u2013colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?","volume":"55","author":"Bonig","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.taap.2020.114976_bb0050","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2017.10.034","article-title":"Comparing granulocyte colony\u2013stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: a meta-analysis of randomised clinical trials in breast cancer patients","volume":"89","author":"Botteri","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.taap.2020.114976_bb0055","series-title":"Seminars in Oncology","first-page":"S15","article-title":"Developing clinical trials for biosimilars","author":"Bui","year":"2014"},{"key":"10.1016\/j.taap.2020.114976_bb0060","first-page":"17","article-title":"Biosimilars in the management of neutropenia: focus on filgrastim","volume":"10","author":"Caselli","year":"2016","journal-title":"Biol: Targets Therapy"},{"key":"10.1016\/j.taap.2020.114976_bb0065","first-page":"188","article-title":"Myeloid growth factors: clinical practice guidelines in oncologyTM","volume":"5","author":"Crawford","year":"2007","journal-title":"JNCCN"},{"key":"10.1016\/j.taap.2020.114976_bb0070","doi-asserted-by":"crossref","first-page":"v248","DOI":"10.1093\/annonc\/mdq195","article-title":"Hematopoietic growth factors: ESMO clinical practice guidelines for the applications","volume":"21","author":"Crawford","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.taap.2020.114976_bb0075","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ajh.10255","article-title":"Severe chronic neutropenia: treatment and follow-up of patients in the severe chronic neutropenia international registry","volume":"72","author":"Dale","year":"2003","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.taap.2020.114976_bb0080","first-page":"7","article-title":"A systematic literature review of the efficacy, effectiveness, and safety of filgrastim","volume":"26","author":"Dale","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.taap.2020.114976_bb0085","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/1471-2407-8-332","article-title":"XM02 is superior to placebo and equivalent to NeupogenTM in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel\/doxorubicin chemotherapy","volume":"8","author":"Del Giglio","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.taap.2020.114976_bb0090","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00002018-200225060-00010","article-title":"Use of measures of disproportionality in pharmacovigilance","volume":"25","author":"Egberts","year":"2002","journal-title":"Drug Saf."},{"key":"10.1016\/j.taap.2020.114976_bb0095","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1080\/10428190902756081","article-title":"XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy","volume":"50","author":"Engert","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.taap.2020.114976_bb0100","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.taap.2020.114976_bb0105","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/pds.4218","article-title":"Comparative study of the number of report and time-to-onset of the reported adverse event between the biosimilars and the originator of filgrastim","volume":"26","author":"Kobayashi","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.taap.2020.114976_bb0110","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3747\/co.2008.198","article-title":"Canadian supportive care recommendations for the management of neutropenia in patients with cancer","volume":"15","author":"Kouroukis","year":"2008","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.taap.2020.114976_bb0115","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients","volume":"106","author":"Kuderer","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.taap.2020.114976_bb0120","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.critrevonc.2013.08.006","article-title":"The five \u201cWs\u201d for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs)","volume":"89","author":"Lambertini","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.taap.2020.114976_bb0125","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2288-14-17","article-title":"Estimating time-to-onset of adverse drug reactions from spontaneous reporting databases","volume":"14","author":"Leroy","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.taap.2020.114976_bb0130","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.clinthera.2009.05.003","article-title":"Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States","volume":"31","author":"Lyman","year":"2009","journal-title":"Clin. Ther."},{"key":"10.1016\/j.taap.2020.114976_bb0135","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1093\/annonc\/mdt226","article-title":"The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"Lyman","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.taap.2020.114976_bb0140","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2165\/11532850-000000000-00000","article-title":"Modelling the time to onset of adverse reactions with parametric survival distributions","volume":"33","author":"Maignen","year":"2010","journal-title":"Drug Saf."},{"key":"10.1016\/j.taap.2020.114976_bb0145","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/annonc\/mdm345","article-title":"The challenge of biosimilars","volume":"19","author":"Mellstedt","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.taap.2020.114976_bb0150","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejbt.2016.10.003","article-title":"Characterization and comparability of biosimilars: a filgrastim case of study and regulatory perspectives for Latin America","volume":"24","author":"Mendoza-Macedo","year":"2016","journal-title":"Electron. J. Biotechnol."},{"key":"10.1016\/j.taap.2020.114976_bb0155","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.drudis.2011.08.001","article-title":"The regulatory framework of biosimilars in the European Union","volume":"17","author":"Minghetti","year":"2012","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.taap.2020.114976_bb0160","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2020.114976_bb0165","first-page":"1991","article-title":"Zarzio\u00ae, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study","volume":"24","author":"Nahon","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.taap.2020.114976_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00002018-199819010-00001","article-title":"The role of the WHO programme on international drug monitoring in coordinating worldwide drug safety efforts","volume":"19","author":"Olsson","year":"1998","journal-title":"Drug Saf."},{"key":"10.1016\/j.taap.2020.114976_bb0175","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40259-014-0088-z","article-title":"Drift, evolution, and divergence in biologics and biosimilars manufacturing","volume":"28","author":"Ramanan","year":"2014","journal-title":"BioDrugs"},{"key":"10.1016\/j.taap.2020.114976_bb0180","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/1096-8652(200103)66:3<178::AID-AJH1042>3.0.CO;2-H","article-title":"Oral combination chemotherapy in conjunction with filgrastim (G-CSF) in the treatment of AIDS-related non-Hodgkin\u2019s lymphoma: evaluation of the role of G-CSF; quality-of-life analysis and long-term follow-up","volume":"66","author":"Remick","year":"2001","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.taap.2020.114976_bb0185","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1517\/14712591003796553","article-title":"Biosimilars: current status and future directions","volume":"10","author":"Roger","year":"2010","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.taap.2020.114976_bb0190","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.taap.2020.114976_bb0195","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1109\/TITB.2005.855566A","article-title":"Evaluation of statistical association measures for the automatic signal generation in pharmacovigilance","volume":"9","author":"Roux","year":"2005","journal-title":"IEEE Trans. Inf. Technol. Biomed."},{"key":"10.1016\/j.taap.2020.114976_bb0200","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.taap.2020.114976_bb0205","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.biologicals.2010.05.002","article-title":"Comparison of the physicochemical properties of a biosimilar filgrastim with those of reference filgrastim","volume":"38","author":"Skrlin","year":"2010","journal-title":"Biologicals"},{"key":"10.1016\/j.taap.2020.114976_bb0210","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update","volume":"33","author":"Smith","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.taap.2020.114976_bb0215","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jiac.2017.12.011","article-title":"Clinical safety and efficacy of \u201cfilgrastim biosimilar 2\u201d in Japanese patients in a post-marketing surveillance study","volume":"24","author":"Tamura","year":"2018","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.taap.2020.114976_bb0220","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/pds.3226","article-title":"Using time-to-onset for detecting safety signals in spontaneous reports of adverse events following immunization: a proof of concept study","volume":"21","author":"Van Holle","year":"2012","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.taap.2020.114976_bb0225","first-page":"e343","article-title":"Estimating the social value of G-CSF therapies in the United States","volume":"22","author":"Vanderpuye-Orgle","year":"2016","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.taap.2020.114976_bb0230","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40264-013-0073-3","article-title":"Traceability of biopharmaceuticals in spontaneous reporting systems: a cross-sectional study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases","volume":"36","author":"Vermeer","year":"2013","journal-title":"Drug Saf."},{"key":"10.1016\/j.taap.2020.114976_bb0235","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1177\/2168479015589822","article-title":"Quantitative methods for the identification of signals for individual case safety reports in India","volume":"49","author":"Vivekanandan","year":"2015","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10.1016\/j.taap.2020.114976_bb0240","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1182\/blood.V88.6.1907.bloodjournal8861907","article-title":"Filgrastim (r-metHuG-CSF): the first 10 years","volume":"88","author":"Welte","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.taap.2020.114976_bb0245","first-page":"1","article-title":"PF-06881893 (NivestymTM), a Filgrastim biosimilar, versus US-licensed Filgrastim reference product (US-Neupogen\u00ae): pharmacokinetics, pharmacodynamics, immunogenicity, and safety of single or multiple subcutaneous doses in healthy volunteers","author":"Yao","year":"2019","journal-title":"BioDrugs"}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X20301009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X20301009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T20:49:47Z","timestamp":1758574187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X20301009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":49,"alternative-id":["S0041008X20301009"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2020.114976","relation":{},"ISSN":["0041-008X"],"issn-type":[{"type":"print","value":"0041-008X"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Towards a comprehensive safety understanding of granulocyte-colony stimulating factor biosimilars in treating chemotherapy associated febrile neutropenia: Trends from decades of data","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2020.114976","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114976"}}